Adaptimmune Therapeutics (ADAPY) AI Stock Analysis

• Market Cap: $16.17M
• Dividend Yield: N/A
• Average Volume (3M): 63.76M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: -53.61%
• EPS Growth: -93.14%
• Country: US
• Employees: 506
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 265,051,600
• 10 Day Avg. Volume: 5,290,195
• 30 Day Avg. Volume: 63,762,501
• PEG Ratio: 0.04
• Price to Book (P/B): 11.47
• Price to Sales (P/S): 0.76
• P/FCF Ratio: -1.79
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.08
• Revenue Forecast (FY): $27.44M

• Rating: 39 Underperform
• Price Target: $0.00 ▼(-100.00% Downside)

The overall stock score of 39 reflects significant financial instability and negative valuation metrics. The technical analysis suggests a bearish trend, further impacting the score. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Proprietary TCR Technology

Adaptimmune's proprietary TCR technology offers a competitive edge in developing targeted cancer therapies, potentially leading to successful treatments and partnerships.

High Gross Profit Margin

A high gross profit margin indicates efficient cost management in production, which can support profitability as revenue stabilizes or grows.

Free Cash Flow Growth

Improvement in free cash flow growth suggests better cash management, providing more resources for strategic investments and operational needs.

Negative Factors

Declining Revenue

Significant revenue decline reflects challenges in market demand or product adoption, potentially impacting long-term financial stability.

Negative Profitability

Ongoing negative profitability suggests operational inefficiencies and may hinder the company's ability to sustain growth without restructuring.

Precarious Balance Sheet

A precarious balance sheet with negative equity raises concerns about financial stability and solvency, limiting strategic flexibility.

Adaptimmune Therapeutics Business Overview & Revenue Model

Company Description

Adaptimmune Therapeutics is a biotechnology company specializing in the development of T-cell therapy for cancer treatment. The company focuses on harnessing the power of the immune system to create innovative therapies that target specific cancer antigens, particularly in the sectors of oncology and immunotherapy. Adaptimmune's core products include its proprietary SPEAR T-cell therapies, which are designed to treat a variety of cancers, including solid tumors and hematologic malignancies.

How the Company Makes Money

Adaptimmune Therapeutics generates revenue primarily through collaborations and partnerships with pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on future sales of therapies developed in partnership. The company may also earn revenue from clinical trial agreements and grants that support its research and development efforts. Additionally, any successful commercialization of its SPEAR T-cell therapies could lead to significant revenue through product sales, particularly if these therapies gain regulatory approval and are adopted widely in clinical settings.

Adaptimmune Therapeutics Financial Statement Overview

Summary

Adaptimmune Therapeutics is facing significant financial challenges, including declining revenues, negative profitability, and a precarious balance sheet. Despite some improvement in free cash flow growth, the company's financial health remains weak, requiring strategic interventions to stabilize and improve its financial position.

Income Statement

Adaptimmune Therapeutics has experienced significant revenue volatility, with a sharp decline in TTM revenue growth of -63.77%. The company maintains a high gross profit margin of 98.06% in TTM, but this is overshadowed by negative net profit margins and EBIT margins, indicating ongoing operational challenges and profitability issues.

Balance Sheet

The balance sheet reveals a concerning financial structure with a negative stockholders' equity in TTM, leading to a negative debt-to-equity ratio. The return on equity is also negative, reflecting substantial losses relative to equity. These factors suggest financial instability and potential solvency risks.

Cash Flow

Cash flow analysis shows a significant free cash flow growth of 73.93% in TTM, but the company still faces negative operating cash flow and free cash flow figures. The operating cash flow to net income ratio is negative, indicating cash flow challenges relative to earnings.

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Adaptimmune Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADAPY, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.10, and below the 200-day MA of 0.23, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 44.62 is Neutral, neither overbought nor oversold. The STOCH value of 72.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADAPY.

Adaptimmune Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MRSN	59 Neutral	$40.72M	-0.55	―	―	-4.76%	8.09%
XLO	54 Neutral	$41.56M	-1.05	-908.28%	―	588.40%	61.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNTI	47 Neutral	$46.27M	-0.54	-394.62%	―	―	78.60%
LVTX	44 Neutral	$42.75M	-1.54	-101.50%	―	-32.06%	16.38%
ADAPY	39 Underperform	$16.17M	―	-1341.37%	―	-53.61%	-93.14%
BCAB	35 Underperform	$68.20M	-1.01	―	―	-100.00%	32.37%